Key PointsQuestionDoes a treat-and-extend regimen of aflibercept or bevacizumab injections have outcomes similar to monthly injections in participants with macular edema associated with central retinal vein occlusion or hemiretinal vein occlusion who have exhibited a good response to 6 months of monthly injections? FindingsIn this secondary analysis of a randomized clinical trial, meaningful visual acuity differences at 12 months were not present in comparisons of participants who had received a treat-and-extend regimen vs patients who received monthly injections between months 6 and 12. MeaningBecause of the wide confidence intervals on visual acuity differences between the monthly and the treat-and-extend groups, caution is warranted before concluding that the 2 regimens are associated with similar vision outcomes.
JAMA Ophthalmology – American Medical Association
Published: Apr 24, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera